Table 1 Demographic data and laboratory characteristics of studied CVID subjects

Median age^a

34.0 (22–65)

36 (21–65)

Gender (male/female)

10/6

7/9

Onset of disease (early/late)^b

9/7

Autoimmunity manifestations (%)

19

Bronchiectasis (%)

62.5

Splenomegaly (%)

43.75

Lymphadenopathy (%)

1.5

GI symptoms (%)

25

Granulomas (%)

12.5

Cancer (%)

12.5

Median duration of IVIg (years)

9.0 (3–15)

Immunoglobulin G (mg/dL)^c

771.5 (459–926)

Immunoglobulin A (mg/dL)

5 (0.2–29.4)

Immunoglobulin M (mg/dL)

10.2 (1.85–32.4)

B cells (CD3− CD19+) (%)

6.6 (4.58–10.13)

30.4 (9.68–40.98)

Naive B cells (IgD+ CD27−) (%)

88.9 (75.78–93.60)

36.65 (31.05–57.50)

Memory B cells (IgD− CD27+) (%)

1.63 (0.4–3.4)

17.75 (11.25–21.20)